# Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects

> **NCT00851773** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 84 (actual)

## Conditions studied

- Diabetes
- Healthy

## Interventions

- **DRUG:** semaglutide
- **DRUG:** semaglutide
- **DRUG:** semaglutide
- **DRUG:** semaglutide
- **DRUG:** semaglutide
- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00851773
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2015-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00851773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00851773, "Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00851773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*